Susan G. Komen® Unveils $26 Million Investment in Research, Focused on Metastatic Breast Cancer and New Treatments

Susan G. Komen, the worlds leading breast cancer organization, today announced $26 million in funding for new research projects that focus on metastatic breast cancer, developing new, more-effective treatments, and addressing disparities in breast cancer outcomes. This years grant slate focuses on key areas that will help the organization achieve its Bold Goal to reduce the current number of breast cancer deaths in the U.S. by 50 percent by 2026.

In order to save more lives, we must address the main cause of breast cancer deaths: metastatic breast cancer, said George Sledge, Susan G. Komens Chief Scientific Advisor, M.D., Professor of Medicine, and Chief of the Division of Oncology in the Department of Medicine at Stanford University.

We are pleased to support research aimed at preventing breast cancers from metastasizing (spreading) and developing new, more effective treatments for metastatic disease, added Komens Chief Scientific Advisor, Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center, Director of the Vanderbilt-Ingram Cancer Center, and B.F. Byrd Jr. Professor of Molecular Oncology, at Vanderbilt University School of Medicine.

Global Banking & Finance Jobs
Search Jobs
 

More than an estimated 154,000 women in the U.S. are living with metastatic breast cancer “ the most advanced stage of breast cancer that has spread outside the breast, often to the brain, bones, liver and lungs. Currently, there is no cure for metastatic breast cancer, and it is responsible for almost all the 42,000 breast cancer deaths in the U.S. each year.

Among the 60 grants Komen awarded, 38 are focused on better understanding and treating metastatic breast cancer. Grants were also given to researchers who are developing new therapies for breast cancer including aggressive subtypes such as triple negative breast cancer, investigating drug resistance, and addressing health disparities in breast cancer outcomes among specific communities.

Breast cancer does not affect everyone equally and with the grants were funding this year, were moving closer to new therapies for aggressive forms of cancer, understanding why treatment doesnt work in some patients and making sure everyone has access to the care they need, said Paula Schneider, CEO, Susan G. Komen.

Komens 2019 portfolio includes*:

  • 60 grants totaling $25,689,384. Of these:
    • 38 grants totaling $17,504,384 are focused on better understanding metastasis “ why it occurs and how to prevent and treat metastatic breast cancer
    • 39 grants totaling $15,579,815 for catalyzing the development of new therapies for all stages of breast cancer
    • 16 grants looking into novel treatments for triple negative breast cancer
    • 14 grants totaling $6,298,750 investigating drug resistance (why drugs stop working in some patients)
    • 9 grants focused on disparities in breast cancer outcomes and
    • 5 that apply big data technology (e.g. Artificial Intelligence, Machine Learning) to breast cancer research

*Eds Note: Numbers add to more than 60 because individual studies may be classed in more than one category.

These new funds bring Komens total research investment in breast cancer to more than $1 billion since opening its doors in 1982, and Komens investment in research focused on metastatic breast cancer to $210 million. Since our inception, we have funded more breast cancer research than any other non-profit outside of the U.S. government. In addition to research, Komen and its nationwide network of Affiliates serve women and men in thousands of communities. To date, more than $2.3 billion has been invested in efforts to provide critical education and real-time support to people in communities across the country.

About Susan G. Komen

Susan G. Komen is the worlds leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Born out of a promise between two sisters, Susan G. Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrows cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social.

Grants are contingent upon signed and executed contracts with Komen.

Sean Tuffnell

Susan G. Komen®

972-855-4382

[email protected]